Deutsch
English
Español
Français
Nederlands
Português
What is Ozempic Breath and Why Is It Driving Mint Sales?
The rising use of GLP-1 weight-loss drugs like Ozempic and Wegovy is creating an unexpected winner in the confectionery world: mint and gum sales. Hershey CEO Kirk Tanner revealed during the company's Q1 2026 earnings call that sales of Ice Breakers mints and gum surged 8% in the first quarter, driven by users seeking relief from a side effect commonly called 'Ozempic breath.' The phenomenon, which causes bad breath and foul-smelling burps, has turned breath-freshening products into an essential accessory for millions of Americans using these medications.
According to Statista, one in eight Americans now uses GLP-1 drugs for weight loss, more than doubling from 5.8% in early 2024 to 12.4% in 2025. This rapid adoption is reshaping consumer behavior in ways that extend far beyond appetite suppression. The CNBC report on Hershey's earnings highlighted that Ice Breakers has become the company's third-largest confection brand, benefiting directly from the GLP-1 trend.
Understanding the Science Behind Ozempic Breath
Ozempic breath, also known as GLP-1 halitosis, stems from several biological mechanisms triggered by semaglutide and similar medications. The primary cause is delayed gastric emptying — the drugs slow down digestion, causing food to remain in the stomach longer and ferment, releasing sulfur compounds that produce a foul, egg-like odor. Additionally, these medications often cause dry mouth (xerostomia) by reducing thirst signals, which decreases saliva production. Saliva naturally cleanses the mouth and controls bacteria; without it, oral bacteria thrive and release additional odor-causing compounds.
Mild ketosis during rapid weight loss adds another layer, producing a fruity or metallic acetone smell on the breath. Unlike ordinary halitosis, this odor often persists despite brushing because its origins are gastrointestinal. The condition is not officially listed as a side effect by Novo Nordisk, but clinical trials show approximately 9% of users report burping (eructation), while over 40% experience nausea and nearly 25% report vomiting. The rising popularity of weight loss drugs has made these symptoms widely discussed among users.
Hershey's Q1 2026 Financial Performance
Hershey reported net sales of $3.10 billion for the first quarter of 2026, beating analyst estimates of $3.03 billion. Adjusted earnings per share came in at $2.35, significantly above the $2.04 forecast. Profits surged 93.6% to $435.1 million, with operating margin jumping to 20.6% from 13.2% a year earlier. The company attributed much of this outperformance to stronger pricing and the unexpected tailwind from GLP-1 drug adoption.
Ice Breakers: The Unexpected Star
Ice Breakers, a brand that includes mints, gum, and breath fresheners, saw retail sales grow by over 8% in Q1. CEO Kirk Tanner described the trend as 'functional snacking,' where consumers choose products that serve a specific purpose beyond simple indulgence. 'We're seeing strong demand for breath-freshening products tied to GLP-1 adoption,' Tanner said during the earnings call. The brand's growth helped offset a 4% decline in North America confectionery volumes, as traditional candy sales face headwinds from health-conscious consumers and economic pressures on lower-income households.
Protein Bars and Healthier Snacks
Hershey's protein bar sales jumped 17% in the quarter, as GLP-1 users prioritize high-protein intake during weight loss to preserve muscle mass. The company's acquisition of LesserEvil, a popcorn brand, contributed 20 percentage points to organic volume growth in North America salty snacks. This dual strategy — catering to both the breath-freshening needs of GLP-1 users and their demand for protein-rich, healthier options — is positioning Hershey to navigate the shifting landscape. The impact of GLP-1 drugs on food companies is prompting major adjustments across the industry.
Broader Industry Impact: The Premium Treat Substitution Effect
Hershey is not alone in benefiting from GLP-1 trends. Lindt & Spruengli reported increased premium chocolate sales among users who trade lower-quality snacks for smaller, higher-quality indulgences. Magnum Ice Cream noted a 'premium treat substitution effect,' where users replace large, low-nutrient snacks with premium, protein-rich options. These patterns suggest that while GLP-1 drugs reduce overall snacking volume, they shift consumption toward higher-value, functional products.
However, Hershey's CFO Steve Voskuil expressed caution, classifying the growing acceptance of GLP-1 medications as one of several 'macro-economic headwinds.' The company maintains its 2026 guidance, but investors are watching closely to see whether the long-term effects of weight loss drugs on consumer behavior will ultimately benefit or harm Hershey's core candy business.
What Consumers Can Do About Ozempic Breath
For those experiencing this side effect, dental and medical experts recommend several strategies:
- Stay hydrated: Drink 80-100 ounces of water daily to combat dry mouth.
- Chew sugar-free gum or mints: Products with xylitol stimulate saliva production and neutralize odors.
- Eat smaller, more frequent meals: This reduces fermentation time in the stomach.
- Avoid sulfur-rich foods: Limit eggs, garlic, onions, and cruciferous vegetables.
- Use a tongue scraper: Remove bacteria that contribute to bad breath.
- Manage acid reflux: Antacids or PPIs may help reduce burping and regurgitation.
Most users find that symptoms peak during the first few months of treatment and improve as the body adjusts to the medication.
Frequently Asked Questions
What is Ozempic breath?
Ozempic breath is a side effect of GLP-1 medications like Ozempic, Wegovy, and Mounjaro, characterized by persistent bad breath and foul-smelling burps. It is caused by delayed gastric emptying, dry mouth, and ketosis.
Does Ozempic officially list bad breath as a side effect?
No, halitosis is not officially listed as a side effect by Novo Nordisk. However, clinical trials report burping in about 9% of users, and dental experts link the drugs to dry mouth, which contributes to bad breath.
How much did Hershey's Ice Breakers sales increase?
Ice Breakers retail sales rose 8% in the first quarter of 2026, driven by GLP-1 users seeking breath-freshening products.
How many Americans use GLP-1 drugs?
According to Statista, 12.4% of U.S. adults (one in eight) use GLP-1 drugs for weight loss as of 2025, up from 5.8% in early 2024.
Will Ozempic breath go away?
For most users, the condition is temporary and improves as the body adapts to the medication, typically within a few months. Staying hydrated and using mints or gum can help manage symptoms.
Follow Discussion